Evidence map›Paper›PMID 32381587›Full record

ArticleMolecular cancer therapeutics2020

The Dysregulated Pharmacology of Clinically Relevant

Kaitlyn J Andreano, Jennifer G Baker, Sunghee Park, Rachid Safi, Sandeep Artham, Steffi Oesterreich, Rinath Jeselsohn, Myles Brown, Sarah Sammons, Suzanne E Wardell and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Kaitlyn J AndreanoDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.
Jennifer G BakerDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.
Sunghee ParkDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.
Rachid SafiDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.
Sandeep ArthamDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.ORCID 0000-0002-0556-8979
Steffi OesterreichDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-2537-6923
Rinath JeselsohnDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-7996-7529
Myles BrownDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Sarah SammonsDepartment of Medical Oncology, Duke Cancer Institute, Duke University, Durham, North Carolina.
Suzanne E WardellDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.ORCID 0000-0002-5792-1447
Ching-Yi ChangDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.
John D NorrisDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.
Donald P McDonnellDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina. donald.mcdonnell@duke.edu.ORCID 0000-0002-7331-4700
Duke University · USDana-Farber Cancer Institute · USDuke Medical Center · USUniversity of Pittsburgh · US

Funding

Pharmacological Sciences Training ProgramT32GM007105 · NIGMS · DUKE UNIVERSITY · PI KUHN, CYNTHIA M · 1985 to 2019
$9.0M
MECHANISM OF ESTROGENS AND ANTIESTROGENSR01DK048807 · NIDDK · DUKE UNIVERSITY · PI MCDONNELL, DONALD P · 1995 to 2019
$4.3M
RIP140 as a mediator of Estrogen Receptor action in tumor associated macrophagesF31CA220978 · NCI · DUKE UNIVERSITY · PI ANDREANO, KAITLYN · 2017 to 2019
$97k
NCI NIH HHS F31 CA220978NIDDK NIH HHS R01 DK048807NIGMS NIH HHS T32 GM007105
6 · The paper itself

Abstract

The estrogen receptor (ER/

Indexed as

MutationAntineoplastic Agents, HormonalBreast NeoplasmsEstrogen Receptor alphaFemaleHumansLigandsProtein BindingSelective Estrogen Receptor ModulatorsTumor Cells, CulturedAntineoplastic Agents, HormonalESR1 protein, humanEstrogen Receptor alphaLigandsSelective Estrogen Receptor Modulators

Identifiers

PMID32381587
PMCPMC7335351
OpenAlexW3022228594

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.